Target detail
ADM
adrenomedullin
Data: Live structured evidence (Supabase)
Foundation row from public.targets — full Open Targets / ChEMBL preload remains a future operator job (Phase 8H+).
Display name: adrenomedullin
Aliases: ADM, adrenomedullin
Type / organism: protein_coding · Homo sapiens
Source: opentargets · ENSG00000148926
Index freshness: last_synced_at 2026-05-15T18:39:37.208+00:00 · updated 2026-05-15T18:39:37.682287+00:00
Limitations & build flags
- Read-only structured navigator
- No clinical outcome benefit inferred
- Trial presence does not imply success
- Drug identity may require normalization
- Terminated/withdrawn trials must remain visible
This symbol is listed in public.targets (operator seed or future preload). Connector-backed sections below may still show empty states until ChEMBL / Open Targets / ClinicalTrials.gov mirror rows exist for this marker.
Connectors represented in loaded rows for ADM. Empty groups mean no matching rows — not a claim about biology or clinical use.
- ClinicalTrials.govLive when indexed
Registry mirror rows in clinical_trials when operators run the CT.gov enrichment CLI — browser never calls the registry directly.
- Open TargetsLive when indexed
Disease–target evidence rows when operators run enrich:opentargets (GraphQL from trusted scripts only).
Rows from disease_target_evidence for this symbol.
glioblastoma
literature · opentargets
Drug records tied via drug_targets — mechanistic linkage only.
No linked drug rows
When drug_targets and drugs rows exist for this symbol, they are listed here.
disease_drug_evidence rows on linked drugs whose evidence_type suggests approved-elsewhere discussion context.
No matching rows
Import repoDB-compatible disease–drug evidence or add structured rows to surface discussion candidates here.
Mirror rows whose text fields mention this symbol — registry context only.
NCT05053880 — A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme
Status: UNKNOWN · clinicaltrials.gov
Open trials hubNCT03660761 — Apatinib in Recurrent or Refractory Intracranial Central Nervous System Malignant Tumors
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT01808820 — Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT00761280 — Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma
Status: TERMINATED · clinicaltrials.gov
Open trials hubNCT02864368 — Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens
Status: TERMINATED · clinicaltrials.gov
Open trials hubNCT00813943 — Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Unmethylated Gene Promoter Status
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT04051606 — Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT01582269 — A Study in Recurrent Glioblastoma (GB)
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT02502708 — Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT04743310 — Fluorescence Detection of Adult Primary Central Nervous System Tumors With Tozuleristide and the Canvas System
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT04209790 — Neoadjuvant Chemoradiation for Resectable Glioblastoma
Status: TERMINATED · clinicaltrials.gov
Open trials hubNCT00797940 — Convection Enhanced Localized Administration of PRX321 With Real-time Imaging for Therapy of Recurrent Glioblastoma (CLARITY-1)
Status: WITHDRAWN · clinicaltrials.gov
Open trials hubNCT01124240 — Temozolomide and Procarbazine With Cilengitide for Patients With Glioblastoma Multiforme Without Methylation of the MGMT Promoter Gene
Status: UNKNOWN · clinicaltrials.gov
Open trials hubNCT07552233 — NK Cell Therapy for Malignant Solid Brain Tumors
Status: RECRUITING · clinicaltrials.gov
Open trials hubNCT01631552 — Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT04444427 — Evaluation of GLR2007 for Advanced Solid Tumors
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT02698280 — Bevacizumab and Nimustine in Patients With Recurrent High Grade Glioma
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT03033524 — Trial to Evaluate the Safety of TTAC-0001(Tanibirumab) in Recurrent Glioblastoma
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT02366728 — DC Migration Study for Newly-Diagnosed GBM
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT00624728 — Assessment of 18FLT PET-CT for Volume Definition of High-grade Gliomas (GLIO-TEP)
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT00584883 — A Phase I Study of ABT 510 for Newly Diagnosed Glioblastoma Multiforme
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT02977780 — INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
Status: RECRUITING · clinicaltrials.gov
Open trials hubNCT01985256 — Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT01607905 — Safety Study of KPT-330 (Selinexor) in Patients With Advanced or Metastatic Solid Tumor Cancer
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT05402241 — IRD at Admission Predicts Survival of GBM Patients - a Prospective Pilot Study
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT02179086 — Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
Status: ACTIVE_NOT_RECRUITING · clinicaltrials.gov
Open trials hubNCT06665724 — Clinical Trial Evaluating Safety of 5-Aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodynamic Therapy (SDT) in Patients With Newly Diagnosed High-Grade Glioma (HGG) Prior to Resection and Standard Adjuvant Therapy (ALA SDT GLIOMA 401)
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT07365280 — Neoantigen-Pulsed Autologous Dendritic Cell Vaccine Combined With Temozolomide for Newly Diagnosed Glioblastoma
Status: NOT_YET_RECRUITING · clinicaltrials.gov
Open trials hubNCT02394665 — Dose Escalated MRSI Guided Radiation Therapy in Glioblastoma
Status: TERMINATED · clinicaltrials.gov
Open trials hubNCT04547621 — HSRT and IMRT Chemoradiotherapy for Newly Diagnosed GBM
Status: UNKNOWN · clinicaltrials.gov
Open trials hubNCT03603379 — Doxorubicin-loaded Anti-EGFR-immunoliposomes (C225-ILs-dox) in High-grade Gliomas
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT04863950 — Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
Status: RECRUITING · clinicaltrials.gov
Open trials hubNCT01478854 — Neural Progenitor Cell Sparing Radiation Therapy Plus Temozolomide
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT05765812 — A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Status: RECRUITING · clinicaltrials.gov
Open trials hubNCT07457307 — Integrating Biology for Safe Intensification of Glioblastoma Hypofractionated Treatment on the MR-Linac
Status: NOT_YET_RECRUITING · clinicaltrials.gov
Open trials hubNCT04945148 — Oxidative Phosphorylation Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temozolomide
Status: RECRUITING · clinicaltrials.gov
Open trials hubNCT01478178 — Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT07485049 — BGB-58067 in Newly Diagnosed Glioblastoma Patients With MTAP-Deleted Tumors
Status: RECRUITING · clinicaltrials.gov
Open trials hubNCT03618667 — GC1118 in Recurrent Glioblastoma Patients With High EGFR Amplification
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT05879367 — Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
Status: RECRUITING · clinicaltrials.gov
Open trials hubNCT04959500 — Newly Diagnosed Glioblastoma
Status: ACTIVE_NOT_RECRUITING · clinicaltrials.gov
Open trials hubNCT00609999 — Ph I Dasatinib + Erlotinib in Recurrent MG
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT03466450 — Glasdegib (PF-04449913) With Temozolomide Newly Diagnosed Glioblastoma
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT02717962 — Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT00939991 — Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT00720356 — Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT06359379 — Ropidoxuridine as a Radiosensitizer in Newly Diagnosed IDH-Wildtype Glioblastoma With Unmethylated MGMT Promoter
Status: TERMINATED · clinicaltrials.gov
Open trials hubNCT04047303 — CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma
Status: TERMINATED · clinicaltrials.gov
Open trials hubNCT03152318 — A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2
Status: ACTIVE_NOT_RECRUITING · clinicaltrials.gov
Open trials hubNCT02575027 — Palliative 4pi Radiotherapy in Treating Patients With Recurrent Glioblastoma Multiforme
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT01342757 — Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT03970447 — A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Status: RECRUITING · clinicaltrials.gov
Open trials hubNCT00916409 — Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT06501911 — A Study of Bicalutamide With Brain Re-irradiation to Treat Recurrent/Progressive High Grade Glioma
Status: WITHDRAWN · clinicaltrials.gov
Open trials hubNCT00723827 — Temodal (Temozolomide) Post Marketing Surveillance Protocol (Study P05557AM2)
Status: COMPLETED · clinicaltrials.gov
Open trials hubNCT06850766 — The Feasibility and Efficacy of Dose Timing (Morning vs Evening) of Temozolomide in the Treatment of Glioblastoma
Status: RECRUITING · clinicaltrials.gov
Open trials hubRepurposing signal rows for drugs linked to this target via drug_targets.
No research signals for linked drugs
Run the deterministic signal builder after drug_targets and source rows are present.
Structured rows with negative evidence_direction on disease–drug or signal tables.
No negative-direction rows
When structured evidence includes explicit negative direction fields, they surface here for oncology review.
- clinicaltrials.gov: 56
- opentargets: 1
Structured evidence rows link this marker to cohort contexts when ingested — interpret as research context only.
Disease contexts
0
Linked drugs
0
Linked in dataset
0
Research signals
0
Doctor-discussion candidate and related tags are descriptive only.
Signals list: Live structured evidence (Supabase)
No matching live evidence found
When repurposing_signal rows reference this marker via linked drugs, summaries appear here.